Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Saved in:
Bibliographic Details
Title: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Authors: Yee AJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Laubach JP; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Campagnaro EL; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., Lipe BC; Department of Hematology/Oncology, University of Rochester, Rochester, NY., Nadeem O; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Friedman RS; Newton-Wellesley Hospital, Newton, MA., Cole CE; Division of Hematology and Oncology, University of Michigan Cancer Center, Ann Arbor, MI., O'Donnell EK; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Bianchi G; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Branagan AR; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Schlossman RL; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Shapiro SJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Harrington CC; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Burke JN; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Gammon MT; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Lively KJ; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Reimonn CA; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Andrade DX; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA., Redd R; Dana-Farber Cancer Institute, Boston, MA., Lohr JG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Anderson KC; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Richardson PG; Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Raje NS; Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
Source: Blood advances [Blood Adv] 2025 Mar 11; Vol. 9 (5), pp. 1163-1170.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024014717